Clinical Trial Update: Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating apatinib for recurrent or refractory intracranial CNS malignant tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intracranial Cns Malignancies
• Intracranial Malignant Cns Tumors
• Intracranial Tumor

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Rongjie Tao | Conditions: Efficacy and Safety | Phase 2 | Status: COMPLETED